Found 13 matching trials
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas PHASE1 Chimeric antigen receptor-modified T cells (CART) holds great promise for t...
Show More Location
Chinese PLA General Hospital
Learn More & Join Trial
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy EARLY_PHASE1 This study is a single-center, open-label clinical trial of single-dose of ...
Show More Location
Affiliated Hospital of Nantong University
Learn More & Join Trial
National Project on Vaccines, COVID-19 and Frail Patients N/A This is a multicentre observational study with the aim of evaluating the an...
Show More Location
IRCCS Istituto Tumori Giovanni Paolo II
Learn More & Join Trial
CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273) PHASE1 Currently, a majority of lymphomas cannot be cured by standard chemo-radiot...
Show More Location
University of Florida
Learn More & Join Trial
Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma EARLY_PHASE1 This study is an exploratory clinical trial of a single-center, open-label,...
Show More Location
The First Affiliated Hospital of Anhui Medical University
Learn More & Join Trial
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas PHASE1 Background:
* Improved treatments for a variety of treatment-resistant, TN...
Show More Location
National Institutes of Health Clinical Center
Learn More & Join Trial
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients. EARLY_PHASE1 This study is a single-center,open-label,single-dose clinical trial of anti...
Show More Location
Multiple Locations
Learn More & Join Trial
CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. PHASE1 HSP-CAR30 is a cell suspension of genetically modified T-cells to express a...
Show More Location
Hospital Santa Creu i Sant Pau
Learn More & Join Trial
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma EARLY_PHASE1 LCCC1852-ATL is a prospective 2-arm study designed to determine if chimeric...
Show More Status
Active Not Recruiting
Location
Lineberger Comprehensive Cancer Center at University of North Carolina
Learn More & Join Trial
Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies PHASE1 The overall purpose of this study is to explore the safety and therapeutic ...
Show More Location
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Learn More & Join Trial